PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: ...

Equities researchers at HC Wainwright boosted their Q2 2025 earnings estimates for shares of BriaCell Therapeutics in a research report issued on Monday, February 3rd. HC Wainwright analyst E. Bodnar ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...

BriaCell Therapeutics Corp. (BCTX, BCTXW) is down by 4.71 percent during Monday morning trading, following the announcement of a ...

Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response ...

H.C. Wainwright analyst Emily Bodnar increased the price target for Briacell Therapeutics (NASDAQ:BCTX) to $32 from the previous $15, while maintaining a Buy rating on the stock. The company, ...

Check the time stamp on this data. Updated AI-Generated Signals for Briacell Therapeutics Corp. (BCTX) available here: BCTX. Type a few symbols and Take a Trial. The signals for these will appear ...

Investing.com -- BriaCell Therapeutics Corp. (NASDAQ: BCTX ...

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today ...